CL2021000882A1 - Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia. - Google Patents

Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia.

Info

Publication number
CL2021000882A1
CL2021000882A1 CL2021000882A CL2021000882A CL2021000882A1 CL 2021000882 A1 CL2021000882 A1 CL 2021000882A1 CL 2021000882 A CL2021000882 A CL 2021000882A CL 2021000882 A CL2021000882 A CL 2021000882A CL 2021000882 A1 CL2021000882 A1 CL 2021000882A1
Authority
CL
Chile
Prior art keywords
vomiting
chemotherapy
nausea
induced
formulations
Prior art date
Application number
CL2021000882A
Other languages
English (en)
Spanish (es)
Inventor
Catherine Jacobson
Original Assignee
Tilray Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tilray Inc filed Critical Tilray Inc
Publication of CL2021000882A1 publication Critical patent/CL2021000882A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/658Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2021000882A 2018-10-10 2021-04-09 Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia. CL2021000882A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862743839P 2018-10-10 2018-10-10

Publications (1)

Publication Number Publication Date
CL2021000882A1 true CL2021000882A1 (es) 2021-08-27

Family

ID=68345091

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000882A CL2021000882A1 (es) 2018-10-10 2021-04-09 Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia.

Country Status (12)

Country Link
US (1) US20200113847A1 (https=)
EP (1) EP3863614A1 (https=)
JP (1) JP2022502471A (https=)
KR (1) KR20210116432A (https=)
AU (1) AU2019357608A1 (https=)
BR (1) BR112021006858A2 (https=)
CA (1) CA3115985A1 (https=)
CL (1) CL2021000882A1 (https=)
CO (1) CO2021005797A2 (https=)
MX (1) MX2021004138A (https=)
PE (1) PE20211198A1 (https=)
WO (1) WO2020077103A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200360292A1 (en) * 2019-05-16 2020-11-19 Aegis Therapeutics, Llc Oil-soluble drug containing compositions and methods of use thereof
CN115968278A (zh) * 2020-05-18 2023-04-14 麦氏生物科技有限公司 脂质-聚合物组合物及使用方法
JP2023546649A (ja) * 2020-09-24 2023-11-07 ニコベンチャーズ トレーディング リミテッド 製剤
US20240252464A1 (en) * 2022-07-06 2024-08-01 Avantsar Sdn Bhd A self-emulsifying drug delivery formulation with improved oral bioavailability of lipophilic compound

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
US20040248970A1 (en) * 2003-04-10 2004-12-09 Webster G.R. Barrie CBD-delta8-THC composition
JP4994039B2 (ja) * 2003-11-26 2012-08-08 スパーナス ファーマシューティカルズ インコーポレイテッド 脂溶性または疎水性化合物の送達に有用なミセル系
WO2006124698A2 (en) * 2005-05-13 2006-11-23 Unimed Pharmaceuticals, Inc. Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
WO2015068052A2 (en) * 2013-10-31 2015-05-14 Full Spectrum Laboratories, Ltd. Terpene and cannabinoid formulations
CA3025208A1 (en) * 2016-05-24 2017-11-30 Bol Pharma Ltd. Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
CA3036585A1 (en) * 2016-09-27 2018-04-05 CannTab Therapeutics Limited Sustained release cannabinoid formulations
US20200163931A1 (en) * 2016-10-12 2020-05-28 Columbia Care Llc Oral composition of extracted cannabinoids and methods of use thereof
US20190336472A1 (en) * 2017-01-03 2019-11-07 Receptor Holdings, Inc. Medicinal compounds and nutritional supplements
EP3582755A4 (en) * 2017-02-15 2020-12-23 Molecular Infusions, LLC PREPARATIONS
US10307392B2 (en) * 2017-10-21 2019-06-04 Alexander Kariman Compound and method for treatment of diseases and disorders
CA3119786A1 (en) * 2017-11-17 2019-05-23 Tilray, Inc. Cannabinoid compositions
EP3755372A1 (en) * 2018-02-23 2020-12-30 Nicola Michael Spirtos Cannabis based therapeutic and method of use
KR20210055042A (ko) * 2018-07-31 2021-05-14 오스칸 그룹 홀딩스 엘티디 “고체의 자가-유화 약학 조성물”

Also Published As

Publication number Publication date
WO2020077103A1 (en) 2020-04-16
US20200113847A1 (en) 2020-04-16
CA3115985A1 (en) 2020-04-16
JP2022502471A (ja) 2022-01-11
KR20210116432A (ko) 2021-09-27
AU2019357608A1 (en) 2021-05-27
MX2021004138A (es) 2021-08-05
BR112021006858A2 (pt) 2021-07-13
PE20211198A1 (es) 2021-07-01
CO2021005797A2 (es) 2021-05-20
EP3863614A1 (en) 2021-08-18

Similar Documents

Publication Publication Date Title
CL2021000882A1 (es) Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia.
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
ECSP19070369A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
NI201900098A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
MX2019002265A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX380767B (es) Métodos para reducir el riesgo cardiovascular.
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
MX2019003134A (es) Terapia de combinacion.
CL2019003572A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
CO2019007879A2 (es) Formas cristalinas de tebipenem pivoxil, composiciones que incluyen a las mismas, métodos de fabricación, y métodos de utilización
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
CL2021001635A1 (es) Tratamiento combinado para tumores sólidos con docetaxel y un inhibidor de cyp3a